Dosimetry study reports favorable tumor-to-organ ratios for Tb-PSMA-617

A registry study (NCT04833517) assessed organ and tumor dosimetry in 15 patients with metastasized castration-resistant prostate cancer treated with [Tb]Tb-PSMA-617 radioligand therapy over a median of 2 cycles. The study reported mean absorbed doses of 0.70 Gy/GBq to kidneys, 0.40 Gy/GBq to parotid glands, 0.36 Gy/GBq to submandibular glands, and 0.13 Gy/GBq to liver, compared with a mean tumor dose of 5.95 Gy/GBq across 43 lesions, yielding tumor-to-kidney and tumor-to-parotid ratios of 10.55 and 16.15 respectively. The authors concluded that Tb-161 delivers high tumor-absorbed doses with tolerable doses to organs at risk, supporting its potential as a radionuclide for PSMA-targeted therapy.

Most relevant for: Patients with metastasized castration-resistant prostate cancer being considered for PSMA-targeted radioligand therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.